Piper Sandler names Illumina a top pick, says genetics company can surge more than 50%

Shares of Illumina can surge more than 50% from here on the back of new product launches, according to Piper Sandler. Analyst David Westenberg named biotech company Illumina a top pick and reiterated his overweight rating on the stock, citing new sequencing products that could drive growth at the company.

Still, the analyst said he approves of the genetics company's competitive position in the industry in his "non consensus call." "Illumina still has a dominant competitive position and is in control of its own pricing structure. We think the company can launch a sequencer where it will see rapid adoption among high throughput users in the academic setting.

Illuminati

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

New company encourages 'donate now, pay later' charitable givingDonating money to charity is good and worthy. But should nonprofits encourage you to go into debt in order to do so? A new VC-funded company, BGenerous, says the answer is yes. no, no, no. you never know what tomorrow may bring. stay within your means. give as generously as that will allow. Nope. Not reading. Don’t care. But nope. Just hard nope. Ever since standard deduction was introduced to the tax process and now not getting much benefit to donating there isn’t much energy to donate to charity. Of course I am speaking for myself
출처: axios - 🏆 302. / 63 더 많은 것을 읽으십시오 »